Description: Semaglutide is a GLP-1 receptor agonist peptide under investigation for its potential in weight management, glycemic control, and cardiovascular health.
Key Research Highlights:
Weight Loss: Up to 14.9% reduction in body weight over 68 weeks.
Glycemic Control: Significant HbA1c reductions in type 2 diabetes patients.
Cardiovascular Benefits: Reduced risk of major adverse cardiovascular events.
Liver Health: Improvement in NASH-related parameters.
Research Application:
Route: Subcutaneous injection
Schedule: Once weekly
Titration Protocol:
Weeks 1–4: 0.25 mg
Weeks 5–8: 0.5 mg
Weeks 9–12: 1.0 mg
Week 13+: 2.0 mg
Note: This is not an exhaustive list and reflects only a limited set data reported in currently available studies.
Availability:
Purity: ≥99% (HPLC-verified)
Form: Lyophilized powder for reconstitution
⚠️ Disclaimer
The statements made on this website have not been evaluated by the US Food and Drug Administration. These are not findings from Raina's Summit, but instead publicly available studies. This product is for research purposes only and is not approved for human consumption or clinical use.
Semaglutide (5mg-30mg)
C187H291N45O59
At Raina's Summit, we are committed to providing research compounds of the highest standard—we perform quality batch testing to verify each product meets a minimum purity of 99% or we guarantee your money back.